Biocryst Pharmaceuticals Inc SEC filings BCRX
Biocryst Pharmaceuticals Inc has 1,000 filings in SEC EDGAR's recent list, going back to Mar 8, 2016. Its latest annual report, Form ARS, was filed on Apr 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 23, 2026 | — |
| DEF 14A | Proxy statement | Apr 23, 2026 | Jun 11, 2026 |
| DEFA14A | Additional proxy material | Apr 24, 2025 | — |
| DEF 14A | Proxy statement | Apr 24, 2025 | Jun 12, 2025 |
| DEFA14A | Additional proxy material | Apr 25, 2024 | — |
| DEF 14A | Proxy statement | Apr 25, 2024 | Jun 12, 2024 |
| DEFA14A | Additional proxy material | Apr 27, 2023 | — |
| DEF 14A | Proxy statement | Apr 27, 2023 | — |
| DEFA14A | Additional proxy material | May 26, 2022 | — |
| DEFA14A | Additional proxy material | Apr 25, 2022 | — |
| DEF 14A | Proxy statement | Apr 25, 2022 | Jun 7, 2022 |
| DEFA14A | Additional proxy material | Apr 13, 2021 | — |
| DEF 14A | Proxy statement | Apr 13, 2021 | May 25, 2021 |
| DEFA14A | Additional proxy material | Mar 31, 2020 | — |
| DEF 14A | Proxy statement | Mar 31, 2020 | May 12, 2020 |
| PRE 14A | Preliminary proxy statement | Mar 19, 2020 | May 12, 2020 |
| DEFA14A | Additional proxy material | Apr 17, 2019 | — |
| DEF 14A | Proxy statement | Apr 17, 2019 | May 29, 2019 |
| DEF 14A | Proxy statement | Sep 28, 2018 | Oct 30, 2018 |
| PRE 14A | Preliminary proxy statement | Sep 18, 2018 | Oct 30, 2018 |
| DEFM14A | Filing | May 30, 2018 | — |
| DEFA14A | Additional proxy material | May 10, 2018 | — |
| DEF 14A | Proxy statement | May 10, 2018 | Jun 20, 2018 |
| DEFM14A | Filing | Mar 29, 2018 | — |
| DEF 14A | Proxy statement | Apr 12, 2017 | May 24, 2017 |
| DEFA14A | Additional proxy material | Apr 12, 2017 | — |
| DEFA14A | Additional proxy material | Apr 11, 2016 | — |
| DEF 14A | Proxy statement | Apr 11, 2016 | May 23, 2016 |
Showing 28 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- BCRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Durham, NC
- SEC filer status
- Large accelerated filer
- SEC CIK
- 882796
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.